INFINITY PHARMACEUTICALS, INC.

INFINITY PHARMACEUTICALS, INC. insiders are currently net sellers of INFI stock, showing bearish sentiment over the past 90 days. Total sales of $487.0M outpace purchases of $206.5M, creating a net outflow of $280.5M.

INFINITY PHARMACEUTICALS, INC. has 34 active insiders who have filed SEC Form 4 transactions in the past 90 days. Medical Co L.p. Rosebay (Executive) leads with 3 transactions totaling $312.7M. Co Beacon (Executive) follows with 3 transactions worth $312.7M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. INFINITY PHARMACEUTICALS, INC.'s current score of 30/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Sep 12, 2023, when Q. Perkins Adelene (Executive) disposed of 410,196 shares at $0.07 per share for $28.7K. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, INFI insider trading sentiment is currently bearish with an Alignment Score of 30/100. The negative net flow of $280.5M shows more selling than buying. However, 4% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like INFINITY PHARMACEUTICALS, INC.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At INFI, we track all Form 4 filings—currently showing 338 transactions from 34 insiders over 90 days.

A 10b5-1 plan allows INFINITY PHARMACEUTICALS, INC. executives to pre-schedule stock sales when they don't possess material non-public information. At INFI, approximately 4% of recent transactions are 10b5-1 trades. The remaining 96% are discretionary trades, which may carry more informational value.

You can monitor INFINITY PHARMACEUTICALS, INC. (INFI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 34 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. INFINITY PHARMACEUTICALS, INC.'s current score of 30/100 indicates moderately bearish sentiment with selling outpacing buying. This is calculated from $206.5M in purchases versus $487.0M in sales over 90 days, resulting in a net flow of -$280.5M.

SEC Form 4 filings are mandatory reports that INFINITY PHARMACEUTICALS, INC. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At INFI, the most common type is "P" with 23 occurrences. The most recent Form 4 was filed on Sep 12, 2023 by Q. Perkins Adelene.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At INFINITY PHARMACEUTICALS, INC., approximately 4% of recent transactions are executed under 10b5-1 plans, while 96% appear to be discretionary trades. The low percentage means most insider activity at INFI represents discretionary decisions with more informational value.